Single Pass Inc. Launches Global Post-Market Evaluation of the Biopsy Tract Closure Device
I use SinglePass on every visceral biopsy for both tumor and parenchyma, including kidney and liver! This innovative device efficiently seals biopsy channels, reducing bleeding risks and improving patient safety across all my biopsy procedures.
Share
Despite the millions of solid organ percutaneous biopsies performed successfully each year, unintended bleeding post-procedure is a real risk requiring additional procedures, longer hospital stays, and increased costs. And in rare instances, the complications can be devastating.
The SinglePass device is designed to cauterize the biopsy tract immediately after tissue extraction, offering a novel approach to reduce bleeding complications, enhance procedural efficiency, and optimize patient observation time.
'Single Pass's global post-market evaluation - B-S.A.F.E. - reflects our commitment to innovation backed by evidence,' said John Zehren, CEO of Single Pass Inc. 'We're honored to work alongside frontline clinicians to validate real-world safety, usability, and performance, bringing an innovative solution for patients undergoing biopsy procedures.'
B-S.A.F.E. is a multicenter post-market device evaluation that will assess reduction in post-biopsy bleeding and complications, post-biopsy observation time and workflow optimization.
'The SinglePass device represents a transformational advancement in the world of core needle biopsy,' said Dr. Alexander Misono, MD, MBA, RPVI, Chief of Interventional Radiology at Hoag Hospital Irvine in Irvine, CA. 'With the ability of SinglePass to provide immediate and reliable tract closure, we are already witnessing an inevitable shift in the way we manage bleeding risk and patient recovery. I'm proud to contribute to this evaluation and help drive the future standard of care.'
"I use SinglePass on every visceral biopsy for both tumor and parenchyma, including kidney and liver!' remarked Dr. Francis Kang, Clinical Chief of Interventional Radiology at Robert Wood Johnson University Hospital in New Brunswick, NJ. 'This innovative device efficiently seals biopsy channels, significantly reducing bleeding risks and improving patient safety across all my biopsy procedures."
For more information, visit www.singlepass.co.
About Single Pass Inc.
Single Pass Inc. is a privately held medical device company dedicated to enhancing safety and workflow efficiency in image-guided biopsy procedures. Its flagship device, the SinglePass Electrocautery Biopsy Closure Device, enables clinicians to cauterize the biopsy tract in a single step, potentially improving patient outcomes and reducing procedural complexity. The company is headquartered in Lake Forest, California.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
36 minutes ago
- Yahoo
Thermo Fisher Scientific (NYSE:TMO) Gains FDA Approval for Rapid Cancer Diagnostic Tool
Thermo Fisher Scientific recently achieved a 7% price increase following the FDA approval of its Oncomine™ Dx Express Test. This approval, enabling rapid genomic testing, bolsters the company's position in precision oncology and positively impacts investor sentiment. The FDA's decision in early July underscored Thermo Fisher's commitment to advancing diagnostic solutions, which aligns with industry trends toward expedited drug development. Additionally, its strategic collaborations and new contracts, such as with the U.S. Department of Defense, provide further support to its market performance. Despite a broader market dip earlier this year, Thermo Fisher's recent achievements contributed to its stock recovery. Every company has risks, and we've spotted 1 risk for Thermo Fisher Scientific you should know about. Find companies with promising cash flow potential yet trading below their fair value. The FDA approval of Thermo Fisher's Oncomine™ Dx Express Test may bolster its long-term revenue prospects by enhancing its precision oncology portfolio. This is expected to propel Thermo Fisher's market position within the fast-growing biopharma services sector. The company's revenue and earnings forecasts might see positive adjustments as this product gains market traction, aligning with its focus on innovative diagnostic solutions. The integration of these advancements could support further share price increases toward the consensus price target of US$554.04, representing a potential appreciation from the current share price. Over a five-year period, Thermo Fisher's total shareholder return, including dividends, amounted to 12.13%. This shows moderate growth compared to the challenging conditions experienced by the broader market, particularly over the past year when Thermo Fisher underperformed the US Life Sciences industry, which recorded a 15.6% decline. Analyzing this context, the recent uptick in share price highlights a rebound from earlier market pressures, as investors respond positively to decisive company actions and innovations. Thermo Fisher's recent initiatives and developments aim to counter macroeconomic challenges, although potential risks from tariffs and policy changes remain. Gain insights into Thermo Fisher Scientific's historical outcomes by reviewing our past performance report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:TMO. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Forbes
an hour ago
- Forbes
Rise In Teen Use Of Nicotine Pouches In U.S. Has Some Experts Alarmed
In this photo illustration, Zyn nicotine cases and pouches are shown.(Photo Illustration by Michael ... More M. Santiago/Getty Images) The Food and Drug Administration authorized the marketing of ZYN nicotine pouch products earlier this year. The agency found that the pouches provide potential health benefits which are 'sufficient to outweigh the risks of the products, including to youth.' At the same time, the agency said it would 'closely monitor youth use.' The pouches are small sachets of nicotine and additives that are placed between the gum and lip. The stimulant is then absorbed into the bloodstream. Pouches have been available for over a decade, but the FDA's marketing authorization of ZYN marks the first time regulators in America have formally endorsed their sale. By providing nicotine to users without the harms from cigarette smoking, the pouches are now formally considered by the FDA to be a harm reduction aid for smokers who wish to quit and reduce exposure to toxic substances. But many who consume these pouches are not smokers and a growing number are not adults. The high nicotine content can lead to addiction, along with potential risks to both cardiovascular and oral health. Overall, Nielsen Scan Track shows that 'monthly Oral Nicotine Pouch unit sales increased significantly, from 327 million in July 2021 to 1046 million in May 2024—more than tripling over this period.' Philip Morris International shipped 202 million cans of ZYN in the first quarter of 2025, up 53% from the same period in 2024. As smoking rates have fallen in the United States and elsewhere, the tobacco industry is aiming to diversify the set of products it sells and this includes nicotine pouches. The company sponsor of ZYN notes that it is committed to responsible marketing practices focused on limiting access in the U.S. to adults 21 years of age and older. The firm does not use social media influencers in the U.S. or people under the age of 35 in promotional materials. Nevertheless, recent data show that use of such products has nearly doubled among teenagers from 2023 to 2024. A newly released Journal of the American Medical Association study shows that nicotine pouches are gaining traction among high school students. Out of more than 10,000 10th- and 12th-grade students, 5.4% said in 2024 they had used nicotine pouches at some point in their lives, compared to just 3% saying the same in 2023, and 2.6% said in 2024 they'd used them in the past month, compared to 1.3% in 2023. Despite not being condoned by the product's manufacturer, social media influencers appear to be aimed at appealing to younger Americans. There's an apparent attractiveness to a product that isn't carcinogenic—at least not proven—and is smokeless. It's also thought that the release of dopamine caused by nicotine may help with mental acuity. But the FDA warned that its marketing authorization does not mean that the products are necessarily safe. When the FDA authorized the sale of 20 Zyn products in flavors like coffee, citrus, and cinnamon in January of this year, it noted it could revoke that permission if there was a substantial rise in youth uptake. As with e-cigarettes before them, researchers are monitoring how young people in particular are adopting what some warn are highly addictive products. ZYN pouches deliver high doses of nicotine, raising concerns among experts about addiction, possible dual use with other tobacco products and possible long-term health consequences. Among other concerned groups, the American Heart Association put out a statement that evaluates the latest published research on these products, their use patterns among youth and adults and the potential health threats they pose. Nicotine can have negative cardiovascular effects, including heightened blood pressure, heart rate and cholesterol. Furthermore, some pouch users have said they suffer from mouth lesions from long-term use. Some experts believe that ZYN nicotine pouches could present an emerging public health concern, especially among adolescents and young adults. Senate Minority Leader Chuck Schumer formally asked the FDA in 2024 to investigate ZYN and its potential effect on teens. Pending future research findings, more monitoring may be needed. In turn, this could lead to an expanded set of regulations together with a more visible public health campaign that issues targeted warnings for youth about possible risks associated with nicotine pouch use.
Business Wire
4 hours ago
- Business Wire
Form 8.3 - Life Science REIT plc
BOSTON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the 'Code') 1. KEY INFORMATION (a) Full name of discloser: Weiss Asset Management LP (Investment Manager of Brookdale International Partners, L.P. and Brookdale Global Opportunity Fund) (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Life Science REIT plc (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A (e) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure 3 July 2025 (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state 'N/A' N/A Expand 2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security. (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any) Class of relevant security: 1p ordinary – 350,000,000 (ISIN: GB00BP5X4Q29) Interests Short Positions Number % Number % (1) Relevant securities owned and/or controlled: (2) Cash-settled derivatives: 5,080,638 1.45 (3) Stock-settled derivatives (including options) and agreements to purchase/sell: TOTAL: 5,080,638 1.45 Expand All interests and all short positions should be disclosed. Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions). (b) Rights to subscribe for new securities (including directors' and other employee options) Class of relevant security in relation to which subscription right exists: N/A Details, including nature of the rights concerned and relevant percentages: N/A Expand 3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in. The currency of all prices and other monetary amounts should be stated. (a) Purchases and sales Class of relevant security Purchase/Sale Number of securities Price per unit N/A N/A N/A N/A Expand (b) Cash-settled derivative transactions Class of relevant security Product description e.g. CFD Nature of dealing e.g. Opening/Closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit 1p ordinary CFD Increasing a long position 100,000 GBP 0.4400 1p ordinary CFD Increasing a long position 8,111 GBP 0.4390 Expand (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit N/A N/A N/A N/A N/A N/A N/A N/A Expand (ii) Exercise Class of relevant security Product description e.g. call option Exercising/ exercised against Number of securities Exercise price per unit N/A N/A N/A N/A N/A Expand (d) Other dealings (including subscribing for new securities) Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable) N/A N/A N/A N/A Expand 4. OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state 'none' None Expand (b) Agreements, arrangements or understandings relating to options or derivatives Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state 'none' None Expand (c) Attachments Is a Supplemental Form 8 (Open Positions) attached? No Expand Date of disclosure: 4 July 2025 Contact name: Mary Merrigan Telephone number: +1 617 778 7775 Expand Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel's website at
